Abstract
Following years in which there were only modest gains in treatment options for non-small cell lung cancer, recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions.
Following years in which there were only modest gains in treatment options for non-small cell lung cancer, recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions.
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO
March 17, 2025
Leighann B. Montoya, DNP, APRN, AGPC-BC, Dorothie Durosier Mertilus, PhD, DNP, APRN, AGNP-C
March 17, 2025
Vivian A. Pham, PharmD, Christopher Selby, PharmD, BCOP
March 17, 2025